Core Viewpoint - ProQR Therapeutics has initiated an underwritten public offering of its ordinary shares to fund research and development, clinical development, and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 15% of the offering amount at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - ProQR plans to utilize the net proceeds from the offering, along with existing cash, primarily for research and development and clinical development of current and future product candidates [2]. - Remaining funds will be allocated for working capital, capital expenditures, and other general corporate purposes [2]. Group 3: Regulatory Filings - A shelf registration statement on Form F-3 was filed with the SEC on September 30, 2024, and became effective on October 10, 2024 [3]. - A preliminary prospectus supplement will be filed with the SEC to describe the terms of the offering [3]. Group 4: Company Overview - ProQR Therapeutics focuses on transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [5]. - The Axiomer™ technology aims to make specific single nucleotide edits in RNA, potentially leading to new medicines for both rare and prevalent diseases [5].

Core Insights - ProQR Therapeutics announced the presentation of preclinical data for its Axiomer™ RNA editing technology and AX-0810 pipeline program targeting cholestatic diseases at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society [1][2] Group 1: Axiomer™ Technology - Axiomer™ is a next-generation RNA base editing technology that allows for specific single nucleotide changes in RNA, potentially leading to new medicines for various diseases [3][4] - The technology utilizes the human cell's own ADAR machinery to convert Adenosine (A) to Inosine (I), which is then translated as Guanosine (G), effectively correcting disease-causing mutations [3] Group 2: Pipeline and Therapeutic Focus - The AX-0810 program specifically targets NTCP to lower bile acid reuptake in cholestatic diseases, with a presentation scheduled for October 8, 2024 [2] - ProQR aims to address both rare and prevalent diseases with unmet medical needs through its proprietary RNA repair platform [4]

Financial Performance - Total revenue for Q2 2024 reached €6,305 thousand, a significant increase from €1,205 thousand in Q2 2023, representing a growth of 424%[6] - The operating result for Q2 2024 was a loss of €3,600 thousand, an improvement compared to a loss of €8,811 thousand in Q2 2023, reflecting a reduction in losses by 59%[6] - The total comprehensive income for the six months ended June 30, 2024, was a loss of €10,074 thousand, compared to a loss of €17,044 thousand in the same period of 2023, showing an improvement of 41%[6] - Basic loss per share for Q2 2024 was €(0.03), an improvement from €(0.10) in Q2 2023[6] - For the three months ended June 30, 2024, the net result was a loss of €2,692,000, an improvement from a loss of €7,977,000 in the same period last year, representing a 66.2% reduction in losses[8] Research and Development - Research and development costs for the six months ended June 30, 2024, were €16,331 thousand, up from €11,969 thousand in the same period of 2023, indicating a rise of 36%[6] - Research and development expenditures are reflected in the income statement, with development expenses currently not capitalized due to unmet criteria[22] - Research and development costs for the six-month period ended June 30, 2024, increased to €16,331,000, compared to €11,969,000 for the same period in 2023, reflecting increased outsourced activities and full-time employee equivalents[49] Assets and Liabilities - Total assets decreased to €118,051 thousand as of June 30, 2024, down from €137,883 thousand at the end of 2023, a decline of 14%[3] - Equity attributable to owners of the Company fell to €32,854 thousand at June 30, 2024, down from €41,390 thousand at December 31, 2023, a decrease of 21%[3] - Cash and cash equivalents decreased to €578,970 thousand as of June 30, 2024, from €118,925 thousand at December 31, 2023, indicating a significant reduction in liquidity[3] - Total current liabilities increased to €37,279 thousand as of June 30, 2024, compared to €34,203 thousand at the end of 2023, an increase of 6%[3] - Other current liabilities decreased to €5,675,000 as of June 30, 2024, from €8,509,000 as of December 31, 2023[28] Cash Flow - Cash used in operating activities for the six months ended June 30, 2024, was €22,747,000, compared to cash generated of €33,513,000 in the same period last year, indicating a significant cash outflow[8] - The cash and cash equivalents at the end of the period were €78,970,000, down from €118,925,000 at December 31, 2023, reflecting a decrease of 33.5%[23] - Interest received during the three months ended June 30, 2024, was €610,000, compared to €685,000 in the same period last year, showing a decrease of 10.9%[8] - The company reported a net cash used in investing activities of €267,000 for the three months ended June 30, 2024, compared to €294,000 in the same period last year[8] Income and Grants - The company recognized grant income of €366,000 for the six-month period ended June 30, 2024, compared to €76,000 in the same period of 2023[47] - During the six-month period ended June 30, 2024, the company reached milestones amounting to $4,500,000 (€4,196,000) under its collaboration agreement with Eli Lilly[46] Borrowings and Tax - The company’s total borrowings as of June 30, 2024, amount to €4,437,000, an increase from €4,292,000 as of December 31, 2023[29] - The current income tax liability amounts to € nil as of June 30, 2024, consistent with December 31, 2023[54] - The company has not recognized any deferred tax asset related to operating losses due to uncertainty in future earnings[54] - Tax losses can be carried forward indefinitely, but offset against taxable profit is limited to the first € 1 million, with only 50% of excess profit eligible for offset[54] Company Structure and Operations - The company operates in one reportable segment focused on the discovery and development of innovative RNA-based therapeutics[15] - Amylon Therapeutics B.V., an 80% subsidiary, had convertible loans with an average interest rate of 8% per annum[53] - In the six-month period ended June 30, 2024, the amount of convertible loans and accumulated interest waived was € nil, compared to € 509,000 for the same period in 2023[53] - Amylon was legally dissolved in the third quarter of 2023[53]

The presentation will be available on ProQR's website under Presentations & Publications. Learn more about ProQR at www.proqr.com. Investor contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Peter Kelleher LifeSci Advisors T: +1 617 430 7579 pkelleher@lifesciadvisors.com LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announ ...

ProQR Therapeutics N.V. (NASDAQ:PRQR) ASGCT Investor Webcast May 9, 2024 8:00 AM ET Company Participants Sarah Kiely - IR Daniel de Boer - Founder and CEO Gerard Platenburg - Chief Scientific Officer Conference Call Participants Jon Wolleben - Citizens JMP Steve Seedhouse - Raymond James Sarah Kiely Thank you, and good day, everyone. We appreciate you joining our event today. Today, we are pleased to highlight new preclinical proof-of-concept data for our AX-0810 program targeting NTCP, which was presented ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2024 and December 31, 2023 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three Month Periods ended March 31, 2024 and 2023 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Month Periods Ende ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 ProQR Announces Year End 2023 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update. "Over the past year as we exclusively focused our strategy on RNA editi ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | PAGE | | | --- | --- | | Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2023 and December 31, | | | 2022 | 1 | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three and Nine Month Periods ended September 30, 2023 and 2022 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2023 and December 31, 2022 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three and Six Month Periods ended June 30, 2023 and 2022 | 1 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Six Month Periods ...